Abstract
Multiple myeloma is a plasma cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow and associated organ damage. Usually, patients with myeloma present with a single monoclonal protein in serum and/or urine constituted by one heavy chain and one light chain. In less than 5% of the patients, more than one monoclonal protein can be identified. The aim of our retrospective multicenter matched case-control study was to describe the characteristics of cases with biclonal myeloma and compare them against a control group of monoclonal myeloma patients matched by age, sex, and year of diagnosis. A total of 50 previously untreated cases with biclonal myeloma and 50 matched controls with monoclonal myeloma were included in this study. The controls were matched (1:1) for age, sex, year of diagnosis, and participating center. There were no differences in the rates of anemia (52 vs. 59%; p = 0.52), renal dysfunction (36 vs. 34%; p = 0.83), hypercalcemia (9 vs. 16%; p = 0.28), or presence of lytic lesions (23 vs. 16%; p = 0.38) between groups. Similarly, there was no difference in the rates of overall response to therapy (85 vs. 90%; p = 0.88) or survival rates of cases with biclonal myeloma and controls with monoclonal myeloma (4-year survival 72 vs. 76%; p = 0.23). Results of our study suggest that patients with biclonal myeloma have similar response and survival rates than patients with monoclonal myeloma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128. doi:10.1038/leu.2013.313
Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719–734. doi:10.1002/ajh.24402
Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV (2011) Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 118(11):2985–2987. doi:10.1182/blood-2011-04-349175
Graziani MS, Lippi U (1986) Multiple myeloma with serum IgM kappa and Bence Jones lambda biclonal gammopathy. Clin Chem 32(12):2220–2221
Smith L, Barlogie B, Alexanian R (1986) Biclonal and hypodiploid multiple myeloma. Am J Med 80(5):841–843
Pizzolato M, Bragantini G, Bresciani P, Pavlovsky S, Chuba J, Vidal R, Rostagno A, Ghiso J (1998) IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. Br J Haematol 102(2):503–508
Bakta IM, Sutarka IN (2000) Biclonal gammopathy in multiple myeloma: a case report. Gan To Kagaku Ryoho 27(Suppl 2):544–548
Chen ZW, Kotsikogianni I, Raval JS, Roth CG, Rollins-Raval MA (2013) Biclonal IgD and IgM plasma cell myeloma: a report of two cases and a literature review. Case Rep Hematol 2013:293150. doi:10.1155/2013/293150
Banerjee A, Pimpalgaonkar K, Christy AL (2016) A rare case of multiple myeloma with biclonal gammopathy. J Clin Diagn Res 10(12):BD03–BD04. doi:10.7860/JCDR/2016/22466.8984
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working G (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. doi:10.1038/sj.leu.2404284
Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91(5):473–475. doi:10.1002/ajh.24319
Paino T, Paiva B, Sayagues JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejia I, Perez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, Garcia-Sanz R, Vidriales MB, Oriol A, Hernandez MT, Echeveste MA, Paiva A, Blade J, Lahuerta JJ, Orfao A, Mateos MV, Gutierrez NC, San-Miguel JF (2015) Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia 29(5):1186–1194. doi:10.1038/leu.2014.321
Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martin-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF (2017) Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia 31(2):382–392. doi:10.1038/leu.2016.211
Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120(5):1067–1076. doi:10.1182/blood-2012-01-405985
Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutierrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28(2):384–390. doi:10.1038/leu.2013.199
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Jurczyszyn, A., Gozzetti, A., Gdula-Argasińska, J. et al. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Ann Hematol 96, 1693–1698 (2017). https://doi.org/10.1007/s00277-017-3084-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-3084-9